• Recruiting

NCT04702425: phase 1: VOB560-MIK665 Combination First in Human Trial in Patients With Hem. Malig.

Updated: May 25

VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)


VOB560

The purpose of the study is to identify doses and schedules of VOB560 and MIK665 that can be safely given and to learn if the combination can have possible benefits for patients with Non-Hodgkin lymphoma (NHL), Multiple Myeloma (MM) or Acute Myeloid Leukemia (AML).


VOB560 and MIK665 are selective and potent blockers respectively of the B-cell lymphoma 2 (BCL2) protein and of the myeloid cell leukaemia 1 (MCL1) protein, proteins that may protect tumor cells from undergoing cell death. VOB560 and MIK665 are designed to block the functions of the BCL2 and MCL1 proteins, so that the tumor cells that rely on these proteins undergo cell death.


Preclinical data suggest that concomitant treatment with VOB560 in combination with MIK665 induces robust anti-tumor activity.


Sponsor

Novartis Pharmaceuticals


Multiple Locations

International Study

 

ClinicalTrials.gov Identifier: NCT04702425


Official Title: A Phase Ib, Multicenter Study of VOB560 in Combination With MIK665 in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma.


First Posted: January 8, 2021


Click here for details on ClinicalTrials.gov

 

Drug: VOB560

Drug: MIK665

 

VOB 560

BCL2 Inhibitor VOB560 (Code C158510)

Bcl-2 Inhibitor S65487

BCL2 Inhibitor VOB560

S 65487

S-65487

S65487

VOB 560

VOB-560

VOB560


MIK665

Mcl-1 Inhibitor MIK665 (Code C133174)

Mcl-1 Inhibitor MIK665

MIK 665

MIK-665

MIK665

S 64315

S-64315

S64315

 

Locations

Europe

Germany

Italy

Spain

Belgium

Finland

Asia

Hong Kong

Israel

Japan

Korea, Republic of





Posts Archive